Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

Citation data:

Circulation, ISSN: 1524-4539, Vol: 127, Issue: 22, Page: 2166-76

Publication Year:
Usage 421
Abstract Views 303
Link-outs 104
Clicks 14
Captures 260
Readers 177
Exports-Saves 83
Social Media 5
Tweets 5
Citations 134
Citation Indexes 134
Repository URL:
10.1161/circulationaha.112.142158; 10.3410/f.718007211.793480402
ClinicalTrials.gov Identifier:
Wallentin, Lars; Lopes, Renato D; Hanna, Michael; Thomas, Laine; Hellkamp, Anne; Nepal, Sunil; Hylek, Elaine M; Al-Khatib, Sana M; Alexander, John H; Alings, Marco; Amerena, John; Ansell, Jack; Aylward, Philip; Bartunek, Jozef; Commerford, Patrick; De Caterina, Raffaele; Erol, Cetin; Harjola, Veli-Pekka; Held, Claes; Horowitz, John D; Huber, Kurt; Husted, Steen; Keltai, Matyas; Lanas, Fernando; Lisheng, Liu; McMurray, John J V; Oh, Byung-Hee; Rosenqvist, Mårten; Ruzyllo, Witold; Steg, Philippe Gabriel; Vinereanu, Dragos; Xavier, Denis; Granger, Christopher B; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators Show More Hide
Faculty of 1000, Ltd.; Ovid Technologies (Wolters Kluwer Health); Lippincott Williams & Wilkins
Medicine; anticoagulation; apixaban; atrial fibrillation; bleeding; stroke; warfarin; Cardiology
Most Recent Tweet View All Tweets
article description
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).